Dysregulation of ß‐catenin, WISP1 and TCF21 predicts disease‐specific survival and primary response against radio(chemo)therapy in patients with locally advanced squamous cell carcinomas of the head and neck

Vyskocil, Erich; Pammer, Johannes; Altorjai, Gabriela; Grasl, Matthäus Ch.; Parzefall, Thomas; Haymerle, Georg; Janik, Stefan; Perisanidis, Christos; Erović, Boban M.

doi:10.1111/coa.13281

Cited by 5 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, it was found that PHF20 and WDR5 directly bind to the WISP1 transcription sequence at the same site, but not the other four genes. By carrying out an in-depth investigation of the functions of WISP1 and BGN, we found a large number of reports linking these genes with the Wnt/β-Catenin signaling pathway (25,(37)(38)(39)(40)(41)(42). Consistently, our PPI analysis of WISP1 indicated that both WISP1 and BGN are closely associated with the Wnt/β-Catenin signaling pathway.…”

Section: Discussionsupporting

confidence: 70%

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

Long

Xing

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Glioblastoma (GBM) stem cells are resistant to cancer therapy, and therefore responsible for tumor progression and recurrence after conventional therapy. However, the molecular mechanisms driving the maintenance of stemness and dedifferentiation are poorly understood. In this study, we identified plant homeodomain finger-containing protein 20 (PHF20) as a crucial epigenetic regulator for sustaining the stem cell-like phenotype of GBM. It is highly expressed in GBM and tightly associated with high levels of aggressiveness of tumors and potential poor prognosis in GBM patients. Knockout of PHF20 inhibits GBM cell proliferation, as well as its invasiveness and stem cell-like traits. Mechanistically, PHF20 interacts with WDR5 and binds to the promoter regions of WISP1 for its expression. Subsequently, WISP1 and BGN act in concert to regulate the degradation of β-Catenin. Our findings have identified PHF20 as a key driver of GBM malignant behaviors, and provided a potential target for developing prognosis and therapy.

show abstract

Section: Discussionsupporting

confidence: 70%

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

Long

Xing

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…This picture in melanoma further strengthens the tumor-facilitating role of CCN4. In a study on head and neck cancer squamous cell carcinoma Vyskocil et al (2019) sought to determine the prognostic and predictive impact of β-catenin, TCF21 and CCN4 expression in 59 untreated patients, with squamous cell carcinomas, who then underwent primary radiotherapy or concomitant chemoradiotherapy. In this prospective cohort study the impact of TNM classification, grading, sex, age, gender, type of therapy, response to therapy and p16 status on disease-specific (DSS) and disease-free survival (DFS) was analyzed.…”

Section: Ccn4mentioning

confidence: 99%

The CCN axis in cancer development and progression

Yeger

Perbal²

2021

J. Cell Commun. Signal.

View full text Add to dashboard Cite

Since the authors first reviewed this subject in 2016 significant progress has been documented in the CCN field with advances made in the understanding of how members of the CCN family of proteins, CCN1‐6, contribute to the pathogenesis and progression, positive and negative, of a larger variety of cancers. As termed matricellular proteins, and more recently the connective communication network, it has become clearer that members of the CCN family interact complexly with other proteins in the extracellular microenvironment, membrane signaling proteins, and can also operate intracellularly at the transcriptional level. In this review we expand on this earlier information providing new detailed information and insights that appropriate a much greater involvement and importance of their role in multiple aspects of cancer. Despite all the new information many more questions have been raised and intriguing results generated that warrant greater investigation. In order to permit the reader to smoothly integrate the new information we discuss all relevant CCN members in the context of cancer subtypes. We have harmonized the nomenclature with CCN numbering for easier comparisons. Finally, we summarize what new has been learned and provide a perspective on how our knowledge about CCN1‐6 is being used to drive new initiatives on cancer therapeutics.

show abstract

“…189 HNSCC patients underwent RT between May 2005 and August 2008 at the Vienna General Hospital, Austria [ 12 , 13 , 14 ] and were therefore evaluated for eligibility. Those with missing data, the occurrence of recurrence, or insufficient follow-up time of fewer than 60 months were initially excluded ( n = 91).…”

Section: Methodsmentioning

confidence: 99%

Long-Term Swallowing Outcome and Dysphagia in Advanced Staged Head and Neck Squamous Cell Carcinomas after Radiotherapy

Yıldız

Erović²,

Janik

2022

JCM

Self Cite

View full text Add to dashboard Cite

Objective: To evaluate the impact of radiotherapy (RT) on dysphagia and long-term swallowing outcome in patients with stage III and IV head and neck squamous cell carcinomas (HNSCCs). Material and Methods: Between 2005 and 2008, 189 patients with HNSCCs underwent primary or adjuvant RT in a curative setting. Long-term swallowing outcome was evaluated in 50 patients. Among them, 26 were further eligible for prospective analysis of long-term swallowing and dysphagia outcome. Medical charts were retrospectively reviewed regarding pre- and post-treatment dysphagia (3 months after last irradiation setting) as well as persisting long-term dysphagia (2019–2021). Results: Pre-treatment dysphagia was observed in 24 (48%) of 50 patients, particularly in oropharyngeal or hypopharyngeal stage III–IV tumors (OR 9.3; p = 0.003). Conversely, 46 patients (92%) complained about post-treatment dysphagic symptoms, which were more commonly seen in patients with positive neck nodes (OR 10.5; p = 0.037). The post-treatment dysphagia rate dropped from 92% to 24% (p < 0.001) during surveillance, which was significantly linked to xerostomia (OR 5.77; p = 0.019), dysgeusia (OR 9.9; p = 0.036) and free flap reconstruction (OR 6.1; p = 0.022). Conclusion: Pretreatment dysphagia is common in advanced stage HNSCCs and almost all patients complain about dysphagia at the end of RT. Importantly, applied RT protocols did not affect long-term dysphagia, which improves significantly in the majority of patients over time. Meeting Information: Preliminary results have been presented at the 65th Annual Meeting of the Austrian Society of Otorhinolaryngology, 22–26 September 2021, Austria.

show abstract

Dysregulation of ß‐catenin, WISP1 and TCF21 predicts disease‐specific survival and primary response against radio(chemo)therapy in patients with locally advanced squamous cell carcinomas of the head and neck

Cited by 5 publications

References 44 publications

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway

The CCN axis in cancer development and progression

Long-Term Swallowing Outcome and Dysphagia in Advanced Staged Head and Neck Squamous Cell Carcinomas after Radiotherapy

Contact Info

Product

Resources

About